01 / DESIGN
What was studied?
An unknown preparation submitted to a laboratory was examined using liquid chromatography and high-resolution tandem mass spectrometry. The investigators interpreted fragmentation data to propose an amino-acid sequence and a terminal modification.
02 / FINDINGS
What did the researchers report?
They identified a 29-amino-acid peptide with a C-terminal amide and discussed its consistency with material marketed as CJC-1295. The paper illustrates how analytical identity can be investigated independently of marketing terminology.
03 / LIMITS
How should it be interpreted?
This is a single analytical investigation, not a clinical trial or a survey of all products. A proposed sequence does not establish purity, sterility, net content or equivalence to an albumin-binding clinical analogue. The original methods and reference materials matter when interpreting identity claims.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.